Related Experiment Videos
[Blood fibronectin changes in various neoplasms]
Presse Medicale (Paris, France : 1983)
|February 8, 1986
Summary
Plasma fibronectin and carcinoembryonic antigen (CEA) show varying frequencies in cancer patients. Fibronectin is more frequently elevated than CEA, especially in mammary adenocarcinoma and metastatic cancers.
Area of Science:
- Oncology
- Biochemistry
Background:
- Plasma fibronectin and carcinoembryonic antigen (CEA) are biomarkers investigated for cancer detection.
- Their diagnostic utility can vary depending on cancer type and stage.
Purpose of the Study:
- To compare the frequencies of plasma fibronectin and CEA in cancer patients.
- To correlate these marker levels with the extent of cancer progression.
Main Methods:
- Analysis of plasma fibronectin and CEA levels in 85 cancer patients.
- Comparison of marker frequencies with cancer type and presence of metastases.
- Correlation of marker levels with the degree of cancer extension.
Main Results:
- Elevated plasma fibronectin was observed in 46% of mammary adenocarcinoma patients, compared to 18% with increased CEA.
- In patients with secondary metastases, over 80% showed abnormal fibronectin levels, versus 50% for CEA.
- Fibronectin elevation was less common in other cancers, except for those of the genital tract.
Conclusions:
- Plasma fibronectin and CEA are not organ-specific tumor markers.
- Fibronectin appears to be a more frequent indicator than CEA in certain cancers, particularly mammary adenocarcinoma.
- The frequency of these markers differs significantly, offering distinct insights into cancer presence and extent.